NDRA · XBRL financial data
ENDRA Life Sciences financial statements, every fiscal year
The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NDRA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | — | — | — |
| Cost of revenue | 0 | — | — | — | — | — |
| Gross profit | 0 | — | — | — | — | — |
| Research and development | 5,918 | 5,483 | 6,554 | 5,004 | 3,190 | 1,850 |
| General and administrative | 5,002 | 4,940 | 5,174 | 4,696 | 7,056 | 3,724 |
| Total operating expenses | 11,502 | 11,498 | 13,158 | 10,521 | 10,817 | 5,763 |
| Operating income (loss) | (11,502) | (11,498) | (13,158) | (10,521) | (10,817) | (5,763) |
| Other income (expense) | 9 | (42) | (22) | 460 | (691) | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | — |
| Net income (loss) | (11,726) | (11,231) | (13,179) | (10,060) | (11,508) | (7,027) |
| Earnings per share, basic USD per share | (0.63) | (0.28) | (4.56) | — | (56.94) | (8.93) |
| Earnings per share, diluted USD per share | — | — | — | (2,766.85) | (56.94) | (8.93) |
| Weighted average shares, basic thousands of shares | — | — | — | — | 202 | 787 |
| Weighted average shares, diluted thousands of shares | — | — | — | 4 | 202 | 787 |
- † Share count changed about 1/14 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/20 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (NDRA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7,227 | 9,462 | 4,889 | 2,834 | 3,229 | 762 |
| Inventory | 590 | 1,285 | 2,645 | 2,623 | 0 | 0 |
| Total current assets | 8,214 | 12,094 | 8,527 | 3,033 | 3,434 | 968 |
| Property and equipment, net | 212 | 131 | 236 | 112 | 69 | 43 |
| Right-of-use asset | 339 | 643 | 506 | 354 | 578 | 462 |
| Total assets | 8,765 | 12,875 | 9,274 | 6,754 | 4,452 | 3,854 |
| Accounts payable | 403 | 791 | 614 | 360 | 270 | 383 |
| Accrued liabilities | — | — | — | — | — | 162 |
| Total current liabilities | 987 | 1,544 | 1,704 | 903 | 605 | 751 |
| Lease liability, non-current | 272 | 518 | 366 | 192 | 487 | 363 |
| Total liabilities | 1,596 | 2,090 | 2,070 | 1,095 | 1,892 | 1,594 |
| Accumulated deficit | (57,338) | (68,691) | (81,870) | (91,930) | (103,438) | (110,466) |
| Total stockholders' equity | 7,169 | 10,784 | 7,205 | 5,659 | 2,560 | 2,260 |
| Total liabilities and equity | 8,765 | 12,875 | 9,274 | 6,754 | 4,452 | 3,854 |
| Common shares outstanding (cover page) thousands of shares | 41,600 | 44,089 | 3,169 | 11,036 | 562 | 1,241 |
- † Share count changed about 1/14 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/20 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (NDRA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (11,726) | (11,231) | (13,179) | (10,060) | (11,508) | (7,027) |
| Stock-based compensation | 2,102 | 1,445 | 1,200 | 996 | 572 | 329 |
| Depreciation and amortization | 99 | 116 | 97 | — | 46 | 44 |
| Net cash from operating activities | (10,747) | (11,122) | (12,769) | (9,549) | (7,401) | (5,183) |
| Purchases of property and equipment | 75 | 45 | 203 | 34 | 16 | 17 |
| Net cash from investing activities | (75) | (45) | (203) | (25) | (13) | (3,017) |
| Proceeds from issuing common stock | 6,781 | 10,616 | 8,400 | 6,483 | 1,148 | 1,218 |
| Proceeds from issuing equity | 1,781 | 10,616 | — | — | — | — |
| Net cash from financing activities | 11,875 | 13,402 | 8,400 | 7,518 | 7,809 | 5,733 |
- † Share count changed about 1/14 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/20 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
| Nu-Med Plus | 5.4 | 0 | 1.1* | 83.5M | — | 10-QJun 30, 2026 |
| INVO Fertility | 3,733 | 2,175 | (1,101)* | 2.5M | 3.4 quarters | 10-QJun 30, 2026 |
| STRATA Skin Sciences | 7,912 | 9,292* | (239)* | 5.9M | 33.1 quarters | 10-KDec 31, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.